NFX.L

Nuformix plc
Nuformix PLC - Result of Annual General Meeting
24th August 2023, 12:22
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3775K
Nuformix PLC
24 August 2023
 

Nuformix plc

("Nuformix" or the "Company")

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing,  announces that the Annual General Meeting of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved on a show of hands at the meeting. 

The results of the proxies appointing the Chair of the meeting are reported below:

 

 

Resolution

Ordinary/ Special

For

 

Against

 

Total votes cast




No. of votes

%

No. of votes

%


1

To re-appoint Daniel Gooding as a director

 

Ordinary

94,720,614

99.67

312,357

0.33%

95,032,971

2

To re-appoint Julian Gilbert as a director

 

Ordinary

94,720,614

99.67

312,357

0.33%

95,032,971

3

To re-appoint s Madeleine Kennedy as a director

 

Ordinary

92,448,034

99.66

312,357

0.34%

92,760,391

4

To authorise the Directors to allot shares.

 

Ordinary

92,082,014

96.19

3,652,015

3.81%

95,734,029

5

To authorise the Directors to disapply pre-emption rights.

 

Special

92,082,014

98.52

1,379,435

1.48%

93,461,449

6

To authorise the Company to purchase its own shares.

 

Special

92,306,372

96.32

3,527,841

3.68%

95,834,213

7

To authorise calling of a general meeting on 14 clear days' notice.

 

Special

93,093,402

97.14

2,740,811

2.86%

95,834,213

 

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 744,309,368 ordinary shares of £0.001 each.

Enquiries:

  

Nuformix plc

 

Dr Daniel Gooding, Executive Director

Dr Julian Gilbert, Non-executive Chairman

 

Via IFC Advisory

 

Stanford Capital Partners Limited

 

Tom Price / Patrick Claridge (Corporate Finance)

+44 (0) 20 3650 3650

John Howes (Corporate Broking)

+44 (0) 20 3650 3652

 

IFC Advisory Limited

 

Tim Metcalfe

Zach Cohen

+44 (0) 20 3934 6630

nuformix@investor-focus.co.uk

               

 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

 

For more information, please visit www.nuformix.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFLFFFTLISFIV ]]>
TwitterFacebookLinkedIn